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Conclusion
Prevalence estimates varied considerably due to differences in the definition used and population assessed. Standardised definitions and studies with representative national samples of MSM are required to improve our understanding of the extent of Chemsex and its associated risks. Longitudinal event-level data for SDU and Chemsex are needed to monitor impact of interventions.
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Introduction:
The relationship between sex and drug use is long established, however the use of drugs in sexual contexts (sexualised drug use) has potential implications for public health. Sexualised drug use (SDU) has been associated with risky sexual behaviours (Digiusto & Rawstorne, 2013; Hegazi et al., 2017; Nodin, Valera, Ventuneac, Maynard, & Carballo-Dieguez, 2011; , increasing the likelihood of participation in condomless sex and thus the risk of sexually transmitted infection (STI) or blood borne virus (BBV) transmission (Olufon & Cathcart, 2016; Ottaway, Finnerty, Amlani, et al., 2017; Page & Nelson, 2016) .
Although not all SDU is problematic, recently emerging patterns of SDU among men who have sex with men (MSM) are a cause for concern and have been identified as a public health priority in a number of countries (EMCDDA, 2017; Heiligenberg et al., 2012; Parsons, Lelutiu-Weinberger, Botsko, & Golub, 2014) .
Patterns of drug use among MSM have changed over the past decade (Ahmed et al., 2016; Adam Bourne et al., 2015; Moncrief, 2014 ) with a notable shift from 'club drugs' such as cocaine and ecstasy to the use of drugs associated with 'Chemsex', namely mephedrone, GHB/GBL, methamphetamine, and to a lesser extent, ketamine. These drugs are often, though not exclusively, used in a sexual context as they act to increase sexual arousal and performance (Ahmed et al., 2016;  Melendez-Torres & Bourne, 2016) whilst encouraging disinhibition. As a result, risk-reduction precautions and intentions to practise safer-sex can often be overruled (Knoops, Bakker, Bodegom, & Zantkuijl, 2015) .
'Chemsex', the use of drugs (particularly methamphetamine, GHB/GBL and mephedrone) before or during planned sexual activity to sustain, enhance, disinhibit or facilitate the sexual experience, also referred to as 'Party and Play' , has been linked to various health harms in a subset of MSM. Chemsex facilitates engagement in lengthy and condomless sex sessions with multiple partners often of unknown serostatus and unknown HIV treatment status, thereby increasing exposure to HIV and multiple STIs. Sexual behaviours such as fisting (ano-brachial intercourse), anilingus (ano-oral sex) and scat play (Gilbart et al., 2015) can place an individual at greater risk of BBVs and gastrointestinal (GI) infections. One such GI infection, Shigella flexneri subtype 3a, has been linked with sexual transmission among MSM during a UK outbreak (Gilbart et al., 2015) .
Although it is difficult to determine whether individuals engaged in Chemsex are just as likely to take sexual risks if they were not under the influence of the drugs (Race, Lea, Murphy, & Pienaar, 2016) , there is some evidence of SDU and CDU's causal association with riskier sexual behaviours (Colfax et al., 2005; Melendez-Torres, Hickson, Reid, Weatherburn, & Bonell, 2017) . MSM participating Chemsex were found to be five times more likely to report more than six sexual partners in the last three months, three times as likely to report use of post-exposure prophylaxis (PEP) and ten times as likely to report group sex, when compared to those not participating in Chemsex (Hegazi et al., 2017) .
As some Chemsex drugs can be injected, a practice referred to as "Slamming", there is the possibility for further exposure to BBVs via injection (Kirby & Thornber-Dunwell, 2013; .
Among MSM in the United Kingdom (UK) SDU is well described, however few studies are designed solely for the collection of data for Chemsex. Internationally however the prevalence of Chemsex among MSM is difficult to determine. Although some data are available (Lea, Reynolds, & De Wit, 2011; Wei, Guadamuz, Lim, Huang, & Koe, 2012) , these data are often not specific to drug use just prior to or during sexual activity ("event-level data") or the MSM population due in part to stigma and discrimination limiting collection of robust data . Data for Chemsex prevalence and associated health harms among other lesbian, gay, bisexual and transgender (LGBT) and heterosexual communities are less frequently captured, though some data are emerging (Beddoes, Sheikh, Khanna, & Francis, 2010; Moncrief, 2014) .
Understanding the extent of the population at risk is essential for determining harms and developing best practice. We therefore aimed to synthesize available evidence in order to better understand the prevalence of Chemsex in MSM in the UK. Evidence was identified through a review of published evidence and examination of national surveillance data. In our review, we distinguish between three forms of substance use: SDU, Chemsex, and the context-independent reporting of Chemsex drug use (CDU) (Box 1). Due to the heterogeneous nature of SDU internationally, this review includes UK data only, to explore consistency of measurement and to highlight gaps in the available knowledge.
Methods:
Our review of available prevalence data for Chemsex, SDU and CDU in the UK consisted of two parts; a scoping literature review and synthesis of available national surveillance data.
Literature Review:
A scoping literature review was conducted using PubMed. We limited the search to identify studies published between January 2007 and 11th August 2017 (the date of this review) which contained UK data. Our review focused on MSM exclusively as, although participation in SDU is not limited to this group (Mayer, Colfax, & Guzman, 2006) , MSM are noted to be at greater risk of the negative outcomes of SDU including transmission of BBVs (HIV and hepatitis B and C) (Ireland et al., 2017; Turner et al., 2006) particularly due to sexual risks.
Our search included a combination of terms associated with; 'Chemsex' or 'sexualised drug use', 'men who have sex with men' and the main Chemsex drugs (see Appendix 1, 2 for search strategy).
A full title screen was conducted removing irrelevant or duplicate articles. Shortlisted titles underwent an abstract review. Full papers were shortlisted and reviewed using the eligibility criteria below.
Publications were included if they contained any prevalence data on Chemsex, SDU and/or the use of any Chemsex drug (mephedrone, GHB/GBL or crystal methamphetamine; CDU) (see Box 1). As polydrug use is common among MSM reporting CDU (Li & McDaid, 2014) , several other substances can be used alongside Chemsex drugs, the most common of these secondary drugs is ketamine (A. Bourne, Reid, Hickson, Torres-Rueda, & Weatherburn, 2014) . Due to this, and ketamine's popularity among MSM internationally, ketamine prevalence data were included in the data synthesis despite the drug not being included in the current UK definition of Chemsex. Publications were excluded if they were; non-English language, non-human or based on non-UK data. Additional publications were found through reviewing citations of included papers.
National Surveillance Data:
Available data from Public Health England's national surveillance systems were extracted to provide a representative data source. National data were included in the synthesis if they contained any prevalence data for Chemsex, SDU or CDU specific to MSM in England. National datasets reviewed included; a drug treatment monitoring surveillance system (Public Health England, 2017a), a survey monitoring BBV prevalence in people who inject drugs (Public Health England, 2017b), a pilot of an enhancement to the national sexually transmitted infection surveillance system (Public Health England, 2015a) and a survey collecting data on crime in England and Wales (Home Office Statistics, 2016).
Synthesis of Prevalence Data:
Prevalence data from eligible publications were extracted and reviewed to determine as to whether they were to event-level (see Box 1). Data were reported by data type (Chemsex, SDU or CDU) alongside details of the population assessed, urban/rural locality and recall period (e.g. use in the last month) (Table 1- 4) . In order to provide context to the data, the purpose of the included studies, the study design, Chemsex definition used and population assessed (sample size, average age, HIV status) were summarized (Appendix 3).
Results:

Literature review:
Our search identified 136 publications (Figure 1 ). From these 51 were excluded as they; were published >10 years ago (n=46) or were not written in English (n=5). Full texts were then assessed and 69 publications were excluded as they; contained no prevalence data (n=22), contained duplicate data already published elsewhere (n=2) and/or contained data not specific to MSM (n=2) or the UK (n=43).
Eligible publications identified in the literature search (n=16) were then included alongside any found through reviewing citations (n=12), into a final data synthesis from 28 eligible publications (Table 1-3) . Table 1 Summary of available data for the prevalence of sexualised drug use among MSM in the UK Table 2 Summary of available data for the prevalence of Chemsex among MSM in the UK Table 3 Summary of available data for the context independent prevalence of Mephedrone, Methamphetamine, GHB/GBL (CDU) and Ketamine β use among MSM in the UK
Overview of the available published data:
Of the 28 eligible publications, 7 reported data for SDU (Table 1) , 4 for Chemsex (Table 2 ) and 23 for CDU (Table 3) , the majority of data were cross-sectional from surveys or case-control studies, with only two studies providing longitudinal data (Appendix 3). Despite ketamine being included in the search criteria alongside the Chemsex drugs, no eligible publications reported prevalence data for the use of ketamine alone.
UK prevalence data captured through these 28 eligible publications were based on sample sizes ranging from 12 to 16,565 MSM (Appendix 3). For 16 of these publications, collection of prevalence data for Chemsex, SDU or CDU among MSM was reported to be the main aim of the study. The remaining studies (n=11) captured prevalence data as an aside to their main aim; to describe factors for BBV acquisition (HIV n=2, HCV n=2), to describe factors for STI acquisition (n=1), as a response to a Shigella outbreak (n=2), for service improvement (n=4) or to assess baseline characteristics for a intervention (n=1) (Appendix 3).
Most publications captured data on both HIV-positive and negative MSM (n=18), four studies focused on HIV-positive MSM and three on HIV-negative MSM alone. The majority of data were collected from urban areas (n=18), with the remainder providing data from both urban and rural localities. No studies collected data from exclusively rural locations. The majority of data were collected through clinic settings (n=19), spread between sexual health clinics (n=12), HIV clinics (n=1), joint HIV and sexual health clinics (n=4) and LGBT drug and alcohol clinics (n=2). Collection of data from community settings or outreach was in the minority (n=2), however online data collection was more common (n=7). Prevalence data were collected for a range of recall periods with some publications providing data for multiple time frames or contexts. Recall periods assessed included both time frame (current involvement (n=3), participation in the last; week (n=1), two weeks (n=1), month (n=6), three months (n=6), year (n=8), and lifetime (n=9) or consistent (n=1) participation) and context driven (most recent CAI (n=1) or reason for clinic presentation (n=2)) periods (Table 1,2,3).
A review of the national surveillance data:
Four national surveillance systems were assessed for Chemsex, SDU or CDU prevalence data, three of which contained relevant data and were included in the synthesis. Annual data from the Crime Survey in England and Wales (Home Office Statistics) was excluded from the synthesis as sexuality data were not collected. Currently little prevalence data for either SDU (n=1) or CDU (n=3) among MSM is captured through national surveillance, with none of the surveillance systems capturing the prevalence of Chemsex in this population (Table 4 ). A national surveillance system monitoring problematic drug use in those attending treatment for drug dependency (Public Health England, 2017a) captures data on the proportion of those presenting to treatment citing problematic use of GHB/GBL and amphetamines, as well as self-reported sexual orientation. Prior to the 2016-2017 reporting period sexuality was not a mandatory field, so completion varied substantially between regions according to local practice. As this data is not currently collected to event-level, it can only be utilised to determine the prevalence of CDU among gay and bisexual men and not Chemsex or SDU specifically.
ii) Genitourinary Medicine Clinic Activity Dataset (GUMCAD) pilot:
A pilot of a behavioural enhancement to routine STI surveillance through GUMCAD was conducted for a consecutive 8-week period at each of 5 sexual health clinics (SHCs) across England in 2015 (Public Health England, 2015a . This provided data on SDU to event-level during last sex as well as CDU prevalence. Data were collected on self-reported sexual risk (same-or different sex partners). The anticipated national rollout for this new version of GUMCAD is in 2018. Once established, this enhanced surveillance system will allow for longitudinal monitoring of behaviour and associated biological outcomes.
iii) Unlinked Anonymous Survey of People Who Inject Drugs :
Data from a national survey monitoring trends in injecting drug use among drug service attendees (Public Health England, 2017b) were collated to determine prevalence of specific drug use and injection, namely mephedrone and ketamine, among male participants reporting to; 1) have ever injected a drug 2) have had sex with a man (MSM) in the last year. Historic data are available since the addition of mephedrone to the survey in 2013. As this survey collects data on both injecting and non-injecting drug use among people reporting to have ever injected drugs, it provides insight into the prevalence of CDU and injected CDU and allows monitoring of trends over time. This survey did not capture any data on the use of other Chemsex drugs (GHB/GBL and methamphetamine) and did not capture drug use to event-level at the time of this review however recent adaptations mean that this data will be available from 2018 onwards.
Data Synthesis:
Prevalence estimates for the extent of SDU, Chemsex and CDU varied considerably depending on the location, timeframe and population assessed ( Table 1 , 2, 3 and 4, Appendix 3). Prevalence estimates for SDU, Chemsex and CDU are presented separately below, as is the extent of this data which is available to event-level (see Box 1).
Sexualised drug use prevalence:
Seven of the 28 eligible publications and only one of the national surveillance systems (GUMCAD)
reported SDU data to event-level. The majority of these recruited both HIV-positive and negative MSM (n=5) from clinic settings (n=6) in exclusively urban areas (n=5). Prevalence estimates for SDU among MSM were mainly collected prospectively (n=4) and range from 4% to 43% depending on the population assessed (Table 1, Appendix 3) .
Across the four publications and single national surveillance system reporting routine SHC attendances by both HIV-positive and HIV-negative MSM, the median prevalence of reported SDU in was 23%, however data captured were based on different recall periods ( When reporting the prevalence of SDU among MSM attending to SHC for post-exposure prophylaxis (PEP), a high prevalence of SDU was identified through a case note review. This study found that 41% of men attending in 2015 reported SDU during the PEP risk event, an increase from 18% in 2013-14, however the size of the sample reviewed was limited (2015: n=101, 2013-14: n=51).
Lifetime reporting of SDU amongst HIV-positive MSM was found to be much lower at just 4% in a retrospective case note review of attendees to a joint HIV and SHC, though this too was limited by a small samples size (n=85) and may be subject to bias due to the retrospective nature of data collection.
Encounter level data were collected through a yearlong community based survey, where MSM were asked to report their last condomless anal intercourse (cAI) session with only one sexual partner in five waves of online data collection. Of the 6,714 encounters reported by the 2,142 MSM surveyed, 43% involved SDU.
Chemsex prevalence:
Limited event-level data were available for Chemsex prevalence (n=4), with only three cross-sectional and one case control study reporting Chemsex prevalence data ( addressed. There was variation in the Chemsex definition used in these studies (Appendix 3), with two studies including secondary drugs such as ketamine and cocaine in their definition for Chemsex.
Chemsex drug use prevalence:
Twenty three studies and three national data sources reported participants' use of various drugs associated with Chemsex, not necessarily in a sexual context, which can be used as a proxy for Chemsex behaviour.
Mephedrone appeared to be the most common Chemsex drug reported by MSM in the UK, with GHB/GBL only becoming more popular when HIV-positive MSM are exclusively or disproportionately recruited. Similarly, mephedrone remained the most popular drug used in the last 3 months (36%) among HIV-negative MSM recruited through a trial for the HIV PrEP ("PROUD" study), followed by GHB/GBL (31%) and finally methamphetamine which was reported by the fewest number of men (18%). The prevalence of ketamine use varied between studies, with nine studies finding it to be the most frequently reported and four studies listing it as the least frequently reported when compared to the three Chemsex drugs.
During the 2015-16 reporting period, NDTMS found 22% of gay and bisexual men presenting to treatment for drug addiction reported problematic use of GBL and 34% reported problematic use of amphetamine. Reported problematic use of these drugs was higher in gay or bisexual men when compared to heterosexuals (where 2% reported problematic GBL use and 6% problematic amphetamine use), as was the reported rate of injecting among those using non-opiate drugs (19% in gay or bisexual men vs 2% in heterosexual men). Among MSM who reported illicit drug use in the last three months 16% reported mephedrone, 16% GHB/GBL and 9% Methamphetamine use. The
Unlinked Anonymous Survey of People Who Inject Drugs collects information on non-injecting and injecting use of mephedrone and ketamine in people attending general drug services who report ever injecting drugs: during 2013-2016 non-injecting use of mephedrone and ketamine in the last month was 15% and 10% respectively among men reporting sex with a man in the last year (injected use estimates are reported in section 3.4 below).
Although the preference for mephedrone seemed to be consistent geographically, regional variations were seen in the reported use of any of the Chemsex drugs and ketamine. UK data extracted from a large international study of over 160,000 MSM, found that within the UK sample (n= 8,291), MSM recruited in London were more likely to report the CDU in the last four weeks than those recruited outside of London (methamphetamine: 3% vs 1%, GHB/GBL: 6% vs 2%, Mephedrone: 5% vs 3%, Ketamine: 6% vs 4%). Further analysis of this data assessed methamphetamine, mephedrone, ketamine and GHB/GBL use by MSM across 44 European cities, and found past four week use to be highest in Brighton (16%), Manchester (16%) and London (13%) relative to other European cities.
Further regional disparity was noted in the Gay Men's Sex Survey which found methamphetamine use among MSM in London to be five times that of outside London (5% vs 1%), with the regional variation (London vs outside London) in reported mephedrone and GHB/GBL only slightly less than this (mephedrone: 12% vs 3% and GHB/GBL: 8% vs 2%).
Injection of Chemsex drugs:
Few Event-level prevalence estimates for SDU in UK MSM also varied greatly and were mainly from urban and clinic based studies (Table 1) . Little national representative data is available for SDU among MSM, and Chemsex remains uncaptured in any of the national surveillance systems (Table 4 ). In order to establish the true extent of Chemsex and SDU among MSM, there is requirement to have a sample representative both in terms of risk and geography, data which is currently lacking.
The majority of data related to the extent of Chemsex in the UK MSM population is from studies collecting data for CDU as a proxy for Chemsex (Table 3) ; however the use of these drugs, particularly mephedrone, will not always be related to sex. Although CDU has been found to be significantly associated with an STI diagnosis in the last year (Sewell et al., 2017) , it is worth noting that not all SDU or Chemsex is problematic and it is possible for participation to be non-detrimental to health and wellbeing if appropriate precautions are made.
To our knowledge, this is the first review of its kind, aiming to summarise available data for the prevalence of Chemsex among MSM in the UK and highlight gaps which limit its comparability and synthesis. It provides a basis from which to build a better understanding of the extent of Chemsex and SDU among MSM and advises as to how best to target future data collection.
Throughout the published literature we found significant variations in the Chemsex definitions used (Appendix 3). Chemsex and SDU were frequently referred to interchangeably, with Chemsex sometimes being incorrectly defined as 'sex under the influence of any illicit drug' (MacRae, Lord, Forsythe, & Sherrard, 2017; Melendez-Torres et al., 2017; Mohammed et al., 2016) . Variations were seen in the drugs included; sometimes solely Chemsex drugs, but often other illicit drugs, such as ketamine, cocaine and/or ecstasy (Chan, Wood, & Dargan, 2015; Gilbart, Simms, Gobin, Oliver, & Hughes, 2013; Hegazi et al., 2017; Schmidt et al., 2016) .
Chemsex drugs were also included as 'Club Drugs', for which definitions were equally as broad and inconsistent (Daskalopoulou et al., 2014; Drumright, Patterson, & Strathdee, 2006; Keogh et al., 2009) , with some including LSD, nitrites (poppers), Rohypnol and Viagra in their definition (Drumright et al., 2006) . Use of a non-standardised definition allows studies to capture poly-drug use, as other drug and substances are often used alongside the three Chemsex drugs when engaging in Chemsex (A. Bourne et al., 2014) . In order to overcome this distorting effect, studies often collated data on individual drug use. However, this limits comparability as individuals may have reported the use of more than one Chemsex drug, making the prevalence estimate for involvement in Chemsex as a whole difficult to determine.
Future data collection should utilise a standardised definition in order to build a strong and comparable knowledge base. For this review we drew upon Public Health England's definition of Chemsex; "the use of drugs before or during planned sexual activity to sustain, enhance, disinhibit or facilitate the experience. Chemsex commonly involves crystal methamphetamine, GHB/GBL and mephedrone, and sometimes the injecting these drugs as slamming)"(Public Health England, 2015b).
This definition highlights the key Chemsex drugs and their use at event-level (i.e. prior to or during sex), providing the specificity and clarity required to form a strong knowledge base. This definition however does not include secondary drugs such as ketamine. This is because the drugs used in Chemsex, and related forms of SDU such as Party and Play (Box 1), vary from country-to-country, reflecting the availability of substances locally. Therefore, whilst our suggested definition works well in the UK, it is likely that definitions for other countries will need to be reflective of local patterns of drug use and thus may include different drugs. Further work is therefore required in order to establish a unifying definition for international comparisons.
Comparison between event-level prevalence estimates was hampered by variation the recall periods assessed (Table 1- 4) . Surveys included in this synthesis of UK data used seven different temporal or context driven (e.g. last PEP/cAI episode) recall periods. A larger quantity of event-level SDU prevalence data was found, however this too is subject to a broad range of prevalence estimates due, in part, to variations in the recall periods addressed.
In the absence of Chemsex or SDU event-level data, CDU can be utilised as a direct proxy for Chemsex, though it is worth noting that CDU is not limited to sexual contexts and Chemsex drugs are used in a range of other settings. Mephedrone was the most popular of the Chemsex drugs used among MSM in the UK potentially due to its availability, low cost and reliable quality (A. Bourne et al., 2014) , although recent data suggests potential for a recent decline in use (Public Health England, 2017c). Similar reasons for use are suggested for GHB/GBL, which was more popular in surveys where HIV-positive MSM were exclusively or disproportionately recruited. This is especially worrying due to the recent observed rise in the number of GHB-associated deaths in London (Hockenhull, Murphy, & Paterson, 2016) . Ketamine appeared to be as popular if not more popular than mephedrone in some studies, however this may reflect the use of both of these drugs being common in non-sexual contexts, when compared to the GHB/GBL and methamphetamine. Methamphetamine use was markedly lower possibly due to its highly addictive nature and association with slamming, although use was higher in London than outside of London and amongst HIV positive individuals.
The majority of the available event-level data were collected through one-off cross-sectional surveys, Little representative national data for SDU and Chemsex were found, however forthcoming adaptations to a national surveillance system of attendees to SHCs (Public Health England, 2015a)
will allow for the collection of event-level data for SDU, and the monitoring of attendee's sexual health over time. Adaptations to another national surveillance system monitoring individuals attending to treatment for drug addiction (Public Health England, 2017a) will mandate the reporting of sexuality, allowing for more easily comparable data over time. Together these will help address the current gaps in data from the UK.
The available prevalence data for Chemsex, SDU and CDU were almost exclusively urban and clinic focused. On the occasion that data from rural localities were captured, it was never reported independently. London appeared to be the focus for data collection, with seven studies reporting exclusively London data and five recruiting from London alongside other urban centres. Data suggest Chemsex is more prevalent in London, Manchester and Brighton (Schmidt et al., 2016) , however anecdotal reports and recent evidence suggesting use of drugs associated Chemsex is common across the UK, has resulted in calls for a targeted sexual health response across the UK (Moncrief, 2014; Wiggins, Mebrahtu, Sullivan, Field, & Hughes, 2016) .
Available Chemsex and SDU prevalence data was often specific to subpopulations of MSM; some assessed MSM engaging in risky sexual behaviours (e.g. cAI), some HIV-positive, some HIV-negative and some a mixture of the above. Although determining Chemsex and SDU prevalence in these subgroups is important when assessing risk and clinical practice, their diversity and biases make it difficult to synthesise data and assess the overall extent of Chemsex.
Estimates for Chemsex were notably higher in HIV-positive MSM and MSM participating in high risk behaviours (cAI) than in those who attended to SHCs. When comparing London based studies, recent participation in Chemsex was found to be more prevalent amongst HIV-positive MSM inpatient admissions when compared to MSM attending two SHCs (31% vs 17%). Higher prevalence of Chemsex in HIV-positive MSM can also be noted in unpublished data (Hibbert et al., In Press; Pufall et al., 2016) . The high levels of Chemsex among these sub-groups is of concern in the context of the possible impact on ART adherence, drug interactions and the subsequent effect on viral load and onwards transmission.
There were several limitations to this scoping review. Firstly, the scope of this review is potentially limited by only having searched a single database. Though measures were taken to capture key publications by reviewing citations in eligible papers, some publications may have been overlooked and therefore not included in the data synthesis. However, as the studies found were heterogeneous and subject to bias, it is unlikely that further studies identified through alternative database searching would have been sufficient to have overcome these limitations and make a full synthesis possible.
Secondly, as this was a scoping and not a systematic review, no formal quality assessment was conducted on the identified publications. Finally only one reviewer screened and assessed articles for eligibility, therefore the inclusion of studies could also have been affected by reviewer bias or subjective views.
This scoping review focused on the use of Chemsex drugs among MSM due to particular concerns regarding infection risk in this population. The prevalence of Chemsex in other groups such as women who have sex with women, female sex workers or HIV positive or high risk heterosexuals has therefore not been examined, even though SDU has been noted in these populations (Marquez, Mitchell, Hare, John, & Klausner, 2009; Moncrief, 2014; Paxton, Williams, Bolden, Guzman, & Harawa, 2013) . A standardised definition and use of recency of drug use instead of a specific recall period would strengthen data collection to allow for a better understanding of the extent of Chemsex, its associated risks and the impact of any future interventions.
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2017)
Retrospective case note review for MSM attendees to two SHCs June 2015 to Jan 2016 Both Urban (London) Current 17%*** (113/655) . Chemsex is the intentional use of drugs that includes mephedrone, crystal methamphetamine (crystal meth), GBL and GHB. These are taken before or during planned activity to sustain, enhance, disinhibit and/or facilitate sexual experience.
Yes: Chemsex
Hegazi 2017
(Hegazi et al.,
2017)
Cross sectional
Analyse associations between SDU, STI diagnoses and sexual behaviour in MSM accessing SHCs to better inform clinical pathways.
2 SHCs, London n= 655 (MSM) Median age: 33 years (range 14-83) HIV positive: (7/655) Chemsex refers to the use of mephedrone, crystallised methamphetamine or GHB/GBL and to a lesser extent cocaine and ketamine to facilitate sex. 
A needs assessment for gay or bisexual men and MSM, assessing their alcohol and drug use.
Online: England n=15360 (MSM) Average age: 34.9 years (SD: 13.1) HIV Positive: 1382/15360 (9%)
Three drugs have recently become closely associated with sex between menmephedrone, GHB/GBL and crystal meth. Combining sex with use of these drugs has become known as Chemsex.
*Authors note that this HIV prevalence is higher than that in the rest of London and UK. 
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